

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of The Securities Exchange Act of 1934

**Date of Report (Date of earliest event reported): April 7, 2015**

---

**GlycoMimetics, Inc.**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-36177**  
(Commission  
File Number)

**06-1686563**  
(IRS Employer  
Identification No.)

**401 Professional Drive, Suite 250**  
**Gaithersburg, MD 20879**  
(Address of principal executive offices, including zip code)

**(240) 243-1201**  
(Registrant's telephone number, including area code)

**N/A**  
(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

---

**Item 7.01 Regulation FD Disclosure.**

On April 7, 2015 GlycoMimetics, Inc. (the “Company”) issued a press release announcing that it has been informed by its collaborator, Pfizer Inc., that Pfizer anticipates initiating a planned Phase 3 clinical trial with rivipansel (GMI-1070) in mid-2015. Pfizer has advised the Company that the clinical supply issue which has delayed the start of this trial has been discussed with the FDA. Under the terms of the license agreement between the two companies, Pfizer is scheduled to make a \$20 million milestone payment to the Company once the first patient is dosed in the Phase 3 clinical trial. This milestone is the second of two scheduled milestone payments totaling \$35 million upon initiation of the Phase 3 clinical trial. Pfizer previously paid the Company \$15 million in May 2014.

A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.****(d) Exhibits**

| <u>Exhibit Number</u> | <u>Exhibit Description</u>   |
|-----------------------|--|
| 99.1                  | Press Release, dated April 7, 2015, “GlycoMimetics Provides Update on Pfizer’s Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015.” |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GLYCOMIMETICS, INC.**

By: /s/ Brian M. Hahn

Brian M. Hahn  
Chief Financial Officer

Date: April 7, 2015

---

**EXHIBIT INDEX**

**Exhibit  
Number**

**Exhibit Description**

99.1 Press Release, dated April 7, 2015, "GlycoMimetics Provides Update on Pfizer's Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015."



**GLYCOMIMETICS PROVIDES UPDATE ON PFIZER'S PLANS TO INITIATE  
PHASE 3 TRIAL WITH RIVIPANSEL IN MID-2015**

*– GlycoMimetics to receive \$20 million milestone payment upon dosing of first patient in trial –*

**GAITHERSBURG, MD, APRIL 7, 2015** – GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that Pfizer (NYSE: PFE) has informed the company that it anticipates initiating a planned Phase 3 clinical trial with rivipansel (GMI-1070) in mid-2015. Pfizer has advised GlycoMimetics that the clinical supply issue which has delayed the start of this trial has been discussed with the FDA. Based on these discussions, Pfizer anticipates the study being able to start enrollment in mid-2015, following FDA review of amended study documents.

Under the terms of the license agreement between the two companies, Pfizer is scheduled to make a \$20 million milestone payment to GlycoMimetics once the first patient is dosed in the Phase 3 clinical trial. This milestone is the second of two scheduled milestone payments totaling \$35 million upon initiation of the Phase 3 clinical trial. Pfizer previously paid GlycoMimetics \$15 million in May 2014. Rivipansel is initially being developed as a potential treatment for vaso-occlusive crisis (VOC) of sickle cell disease. Under the license agreement, Pfizer is responsible for the clinical development and regulatory submission and, if approved, the commercialization of rivipansel.

“Pfizer’s commitment to initiating the rivipansel Phase 3 clinical trial represents a key step in the development of this potentially important new medication for treatment of pain crisis associated with sickle cell disease.” said Rachel King, Chief Executive Officer, GlycoMimetics.

Rivipansel has received both Orphan Drug and Fast Track status for the treatment of VOC from the FDA, and Orphan Product status in the European Union.

**About GlycoMimetics, Inc.**

GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics entered into an exclusive license agreement with Pfizer for rivipansel in October 2011. Under the license agreement, Pfizer is responsible for the clinical development, regulatory approval and potential commercialization of rivipansel. A GlycoMimetics wholly-owned candidate therapy (GMI-1271) for acute myeloid leukemia (AML) and other blood disorders is also in clinical trials. Glycomimetics are molecules that mimic the structure of

---

carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, GlycoMimetics is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Learn more at [www.glycomimetics.com](http://www.glycomimetics.com).

**Cautionary Note Regarding Forward-Looking Statements**

This press release contains forward-looking statements regarding the clinical development of rivipansel, including expected milestone payments from Pfizer. Actual results may differ materially from those in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing GlycoMimetics, please see the risk factors described in the Company's annual report on Form 10-K that was filed with the U.S. Securities and Exchange Commission on March 16, 2015, and other filings the Company makes with the SEC from time to time. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.

###

Source: GlycoMimetics

**Investor Contact:**

Shari Annes  
Phone: 650-888-0902  
Email: [sannes@annesassociates.com](mailto:sannes@annesassociates.com)

**Media Contact:**

Jamie Lacey-Moreira  
Phone: 410-299-3310  
Email: [jamielacey@presscommpr.com](mailto:jamielacey@presscommpr.com)